Recent discussions toward regulatory implementation of the new occupational equivalent dose limit for the lens of the eye and related studies in Japan.

Int J Radiat Biol

c Radiation Protection Department, Nuclear Fuel Cycle Engineering Laboratories, Japan Atomic Energy Agency , Ibaraki , Japan.

Published: August 2019

In 2011, the International Commission on Radiological Protection (ICRP) recommended an equivalent dose limit for the lens of the eye of 20 mSv/year, averaged over defined periods of 5 years, with no single year exceeding 50 mSv for occupational exposure in planned exposure situations. Since then, there have been extensive discussions toward regulatory implementation of such a new occupational lens dose limit. This paper provides an overview of the recent discussions toward regulatory implementation and the current status of the studies related to radiation exposure of the lens and its effect in Japan. In Japan, the Radiation Council established a Subcommittee in July 2017 to discuss the feasibility of implementing the new occupational lens dose limit. In March 2018, the Radiation Council requested all relevant government ministries and agencies to take necessary actions toward implementation of the new occupational lens dose limit, considering a series of discussions made by the Subcommittee. According to the currently available information, the new occupational lens dose limit (20 mSv/year, averaged over defined periods of 5 years, with no single year exceeding 50 mSv) will be implemented into regulations in Japan, most likely in April 2021, albeit subject to change. In particular, there were extensive discussions about reduction of a dose limit and radiation control for workers who may exceed 20 mSv per year, such as the Fukushima Daiichi Nuclear Power Plant decommissioning workers and medical staff, and measurement of 3 mm dose equivalent. In order to underpin regulatory practice, epidemiological and biological studies on radiation effects on the lens and studies on lens dose measurements have been conducted in Japan, some of which have been funded by the Japanese Nuclear Regulation Authority.

Download full-text PDF

Source
http://dx.doi.org/10.1080/09553002.2019.1605464DOI Listing

Publication Analysis

Top Keywords

dose limit
28
lens dose
20
occupational lens
16
discussions regulatory
12
regulatory implementation
12
implementation occupational
12
dose
9
lens
9
equivalent dose
8
limit lens
8

Similar Publications

The efficacy of photodynamic treatment (PDT) against deep-seated tumor is hindered by low penetration depth of light as well as hypoxic conditions which prevails in tumor. To overcome this limitation, Near-infrared (NIR) absorbing photosensitizers have been investigated actively. In the present study we evaluated the PDT efficacy of an NIR absorbing chlorophyll derivative 'Cycloimide Purpurin-18 (CIPp-18)' in Human Breast carcinoma (MCF-7) and cervical adenocarcinoma (Hela) cells under normoxic and hypoxic conditions.

View Article and Find Full Text PDF

Venetoclax plus azacitidine represents a key advance for older, unfit patients with acute myeloid leukemia (AML). The chemotherapy and venetoclax in elderly AML trial (CAVEAT) was first to combine venetoclax with intensive chemotherapy in newly diagnosed patients ≥65 years. In this final analysis, 85 patients (median age 71 years) were followed for a median of 41.

View Article and Find Full Text PDF

Characterisation of the ocular inflammatory response to AAV reveals divergence by sex and age.

Mol Ther

January 2025

Academic Unit of Ophthalmology, Translational Health Sciences, University of Bristol, Bristol, BS8 1TD, UK; NIHR Biomedical Research Centre of Ophthalmology, Moorfields Eye Hospital, London, EC1V 2PD, UK. Electronic address:

Progress for ocular AAV gene therapy has been hindered by AAV-induced inflammation, limiting dose escalation and long-term efficacy. Broadly, the extent of inflammatory responses alters with age and sex, yet these factors are poorly represented in pre-clinical development of ocular AAV gene therapies. Here, we combined clinical imaging, flow cytometry and bulk-sequencing of sorted microglia to interrogate the longitudinal inflammatory response following intravitreal delivery of AAV2 in young (3-month), middle aged (9-month) and old (18-month) Cx3cr1-creER:R26tdTomato+/- mice of both sexes.

View Article and Find Full Text PDF

Sarcopenia, the pathological age-related loss of muscle mass and strength, contributes to physical decline, frailty, and diminished healthspan. The impact of sarcopenia is expected to rise as the aging population grows, and treatments remain limited. Therefore, novel approaches for enhancing physical function and strength in older adults are desperately needed.

View Article and Find Full Text PDF

The approved intravenous adeno-associated virus (AAV) therapies are limited by the widespread prevalence of pre-existing anti-AAV antibodies in the general population, which are known to restrict patients' ability to receive gene therapy and limit transfection efficacy in vivo. To address this challenge, we have developed a novel recombinant human immunoglobulin G degrading enzyme KJ103, characterized by low immunogenicity and clinical value for the elimination of anti-AAV antibodies in gene transfer. Herein, we conducted two randomized, blinded, placebo-controlled, single ascending dose Phase I studies in China and New Zealand, to evaluate the pharmacokinetics, pharmacodynamics, safety and immunogenicity of KJ103 in healthy volunteers.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!